

Hoarseness

Treatment with Bioregulatory Medications

By Jacques Deneef, MD

Hoarseness refers to the symptom of changed quality or volume of sound produced when trying to speak. A diagnosis of hoarseness is termed *dysphonia*.^{1,2} The pitch or quality of sound when someone has hoarseness has been characterized in a number of different ways, including “raspy,” “scratchy,” “husky,” “weak,” and “breathy.”³

Hoarseness is a common symptom affecting up to approximately 20 million people in the U.S. at any given time, and about one in three individuals becoming hoarse at some point in their life.¹ Furthermore, there is a widespread impact from hoarseness, leading to frequent healthcare visits and several billion dollars in lost productivity annually from work absenteeism.¹

Although hoarseness might develop in all ages and in both sexes, there is a much higher occurrence in women; in children between the ages of 8 and 14 years; and in those with certain occupations, including teachers and singers, who frequently use their voice.³ Other risk factors for the development of hoarseness are tobacco smoke (primary or secondary exposure), misuse of alcohol, long-term exposure to dusts and vapors, humidity (excess or deficient), and previous or concurrent upper respiratory tract infection (eg, with a rhinovirus or an influenza virus).

Some of the well-characterized etiologies include laryngitis (viral, bacterial, or allergic),⁴ gastroesophageal

reflux (eg, in professional singers because of the strong intra-abdominal pressure and anxiety of singing),⁵ drugs (eg, steroid inhalers used for asthma),⁶ and malignancy. For example, laryngeal cancer is one of the most common head and neck cancers in the United States, with an estimated 12 290 adults (9920 men and 2370 women) diagnosed in

2009 and potentially up to 3660 deaths (2900 men and 760 women) annually.^{7,8} Hypopharyngeal cancer is another type of malignant cause of hoarseness, with an estimated 2400 adults (1900 men and 500 women) diagnosed every year in the United States and an etiology linked to misuse of alcohol and tobacco and iron and vitamin C deficiency.⁹

Table. Treatment for Hoarseness^a

Basic and/or Symptomatic	Optional
<ul style="list-style-type: none"> • Phosphor-Homaccord • Arnica-Heel (if severe concomitant infection) 	<ul style="list-style-type: none"> • Tartephedreel (if postnasal drip) • Gripp-Heel (if caused by influenza) • Drosera-Homaccord (if spasmodic cough or croup) • Vinceel (for viral pharyngitis) • Spascupreel (if laryngospasms occur) • Aconitum-Homaccord (for a croup-like cough) • Bronchalis-Heel (for chronic smokers) • Husteel (for irritating and tickling cough with spasms) • Echinacea compositum (for any bacterial infection)
<p>Dosages: Phosphor-Homaccord and Arnica-Heel, 8 to 10 drops 3 times per day. Optional therapy: ampoules, 1 ampoule 1 to 3 times per week; drops, 10 drops 3 times per day; tablets, 1 tablet 3 times per day; throat spray, 1 spray 3 times per day.</p>	

Abbreviation: DET, Disease Evolution Table.

^a There is no regulation therapy/3-pillar approach for hoarseness because treatment is based on the symptoms of the patient and the specific etiological factors.

Hypertrophic chronic laryngitis refers to a type of hoarseness that develops after persistent irritation to the larynx from misuse of alcohol, tobacco smoking, toxic vapors, and chronic rhinosinusitis.¹⁰ The larynx is erythematous, with simple thickening of vocal cords and chronic hypersecretion of mucous due to the secondary infection. The voice has a modified timbre and weakens substantially with changes in temperature and during various times of the day, such as the evening.¹¹ Another cause of hoarseness that is more frequent in adults than children is vocal polyps or nodes. The vocal node develops because of an inherent dysfunction of the vocal cords, overuse and abuse of the vocal cords, localized bleeds, and/or inflammatory factors. It presents as an intermittent type of dysphonia with progressive symptoms.¹²

Hoarseness is only a symptom and, therefore, the best management is to determine and treat the underlying cause. Depending on the etiology, natural health products, such as antihomotoxic medications, can be used as safe and effective stand-alone therapies or in conjunction with mainstream medical therapies. A bio-regulatory protocol for the symptomatic treatment of hoarseness is shown in the Table. ■

References

1. Barclay L. Guideline issued for evaluation and management of hoarseness. Medscape Web site. <http://www.medscape.com/viewarticle/708360>. Published September 3, 2009. Accessed June 24, 2010.
2. Feierabend RH, Shahram MN. Hoarseness in adults. *Am Fam Physician*. 2009;80(4):363-370.
3. Hoarseness. MedlinePlus Web site. <http://www.nlm.nih.gov/medlineplus/ency/article/003054.htm>. Updated October 10, 2008. Accessed June 24, 2010.
4. Simpson CB, Fleming DJ. Medical and vocal history in the evaluation of dysphonia. *Otolaryngol Clin North Am*. 2000;33(4):719-730.
5. Modlin IM, Moss SF, Kidd M, Lye KD. Gastroesophageal reflux disease: then and now. *J Clin Gastroenterol*. 2004;38(5):390-402.
6. DelGaudio JM. Steroid inhaler laryngitis: dysphonia caused by inhaled fluticasone therapy. *Arch Otolaryngol Head Neck Surg*. 2002;128(6):677-681.
7. American Cancer Society. Cancer Facts and Figures 2009. American Cancer Society Web site. <http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2009>. Accessed June 24, 2010.
8. Iqbal N, Lo S, Frazier AJ, et al. Laryngeal carcinoma. eMedicine Web site. <http://emedicine.medscape.com/article/383230-overview>. Updated March 3, 2010. Accessed June 24, 2010.
9. Quon H, Goldenberg D. Hypopharyngeal cancer. eMedicine Web site. <http://emedicine.medscape.com/article/1375268-overview>. Updated July 8, 2008. Accessed June 24, 2010.
10. Silva L, Damrose E, Bairão F, Della Nina ML, Junior JC, Olival Costa H. Infectious granulomatous laryngitis: a retrospective study of 24 cases. *Eur Arch Otorhinolaryngol*. 2008;265(6):675-680.
11. Eisenbeis JF, Fuller DP. Voice disorders: abuse, misuse and functional problems. *Mo Med*. 2008;105(3):240-243.
12. Buckmire RA. Vocal polyps and nodules. eMedicine Web site. <http://emedicine.medscape.com/article/864565-overview>. Updated September 8, 2008. Accessed June 24, 2010.

Hans-Heinrich Reckeweg Award 2011

Join in – have your experience rewarded

Heel annually honors outstanding scientific research in the field of a unique homeotherapeutic system (homotoxicology) with the Hans-Heinrich Reckeweg Award.

The main award (€ 10,000)

is presented for scientific work of fundamental theoretical and/or practical significance in antihomotoxic medicine in the fields of human and veterinary medicine.

The incentive award (€ 5,000)

is presented for promising results arising from clinical, case-based or fundamental research in antihomotoxic medicine in the fields of human and veterinary medicine. The prize money is intended to fund further research.

Both prizes are awarded for research carried out in a laboratory or registered practice. All results must be new, convincing and previously unpublished, and research should not have involved animal testing. The deadline for submissions is May 31, 2011.

For more information contact:

Biologische Heilmittel Heel GmbH,

Department of Research,

76532 Baden-Baden, Germany

Phone +49 7221 501-227,

Fax +49 7221 501-660, info@heel.de,

www.heel.com

